# FocaL Mass Drug Administration for Vivax Malaria Elimination

> **NCT05690841** · PHASE3 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 7530 (estimated)

## Conditions studied

- Plasmodium Vivax Malaria
- Malaria

## Interventions

- **DRUG:** Focal Mass Drug Administration (fMDA)

## Key facts

- **NCT ID:** NCT05690841
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-14
- **Primary completion:** 2027-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 7530 (ESTIMATED)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05690841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05690841, "FocaL Mass Drug Administration for Vivax Malaria Elimination". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05690841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*